- Home
- OCCI vs TNXP Comparison
OCCI vs TNXP Comparison
Compare OCCI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCCI
- TNXP
- Stock Information
- Founded
- OCCI N/A
- TNXP 2007
- Country
- OCCI United States
- TNXP United States
- Employees
- OCCI N/A
- TNXP N/A
- Industry
- OCCI Trusts Except Educational Religious and Charitable
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- OCCI Finance
- TNXP Health Care
- Exchange
- OCCI Nasdaq
- TNXP Nasdaq
- Market Cap
- OCCI 146.8M
- TNXP 207.5M
- IPO Year
- OCCI N/A
- TNXP N/A
- Fundamental
- Price
- OCCI $6.18
- TNXP $39.78
- Analyst Decision
- OCCI
- TNXP Strong Buy
- Analyst Count
- OCCI 0
- TNXP 2
- Target Price
- OCCI N/A
- TNXP $585.00
- AVG Volume (30 Days)
- OCCI 115.8K
- TNXP 1.3M
- Earning Date
- OCCI 12-11-2023
- TNXP 05-12-2025
- Dividend Yield
- OCCI 24.32%
- TNXP N/A
- EPS Growth
- OCCI N/A
- TNXP N/A
- EPS
- OCCI N/A
- TNXP N/A
- Revenue
- OCCI N/A
- TNXP $10,041,000.00
- Revenue This Year
- OCCI N/A
- TNXP $12.17
- Revenue Next Year
- OCCI $10.19
- TNXP $789.15
- P/E Ratio
- OCCI N/A
- TNXP N/A
- Revenue Growth
- OCCI N/A
- TNXP N/A
- 52 Week Low
- OCCI $5.47
- TNXP $6.76
- 52 Week High
- OCCI $10.15
- TNXP $558.08
- Technical
- Relative Strength Index (RSI)
- OCCI 42.48
- TNXP 74.56
- Support Level
- OCCI $5.95
- TNXP $25.40
- Resistance Level
- OCCI $6.82
- TNXP $37.84
- Average True Range (ATR)
- OCCI 0.14
- TNXP 4.17
- MACD
- OCCI -0.06
- TNXP 1.75
- Stochastic Oscillator
- OCCI 28.09
- TNXP 87.00
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.